二甲双胍对降低2型糖尿病患者阿尔茨海默病发病率的效果分析(1)
[摘要]目的 探究二甲双胍对降低2型糖尿病患者阿尔茨海默病(AD)发病率的效果。方法 选取我院2017年1～12月收住的90例2型糖尿病患者，按随机数字表法分成观察组与对照组，每组各45例。观察组采用二甲双胍治疗，对照组采用阿卡波糖片治疗。比较两组实施不同治疗的效果、胰岛素抵抗(HOMA-IR)及AD、不良反应发生率的影响。结果 观察组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、空腹胰岛素(FINs)、糖化血红蛋白(HbA1c)、外周血白细胞、体重指数(BMI)均显著低于对照组(P<0.05)，而血维生素B12、连接肽(C肽)显著高于对照组(P<0.05)，且观察组HOMA-IR显著低于对照组(P<0.05)，AD不良反应发生率显著低于对照组，差异均有统计学意义(P<0.05)。结论 将二甲双胍应用于2型糖尿病患者，不仅能降低HOMA-IR，降低AD发生率，还能改善患者相关指标，维持血糖稳定，且不良反应发生率较低，值得应用与推广。
[关键词]2型糖尿病；二甲双胍；阿尔茨海默病；治疗效果
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2018)5(a)-0135-03
[Abstract]Objective To explore the effect of Metformin on reducing the incidence rate of Alzheimer′s disease (AD) in the patients with type 2 diabetes mellitus.Methods A total of 90 patients with type 2 diabetes mellitus who were admitted to our hospital from January to December in 2017，were selected as the research subjects，and were randomly divided into observation group and control group according to the random number table，45 patients in each group.The observation group were given Metformin，and patients in the control group were given Acarbose Tablets for treatment.The effect of different treatment methods on the therapeutic effect，insulin resistance (HOMA-IR)，AD，and incidence rate of adverse reactions were compared between the two groups of patients.Results The observation group was significantly lower than that in the control group in terms of fasting plasma glucose(FBG)，2 h postprandial blood glucose(2 h PG)，fasting insulin(FINs)，glycosylated hemoglobin (HbA1c)，peripheral blood leukocyte，body mass index(BMI) (P<0.05).The blood vitamin B12 and connecting peptide (C peptide) were significantly higher than that in the control group(P<0.05).The observation group was significantly lower than that in the control group in terms of HOMA-IR(P<0.05).The incidence rate of AD and adverse reactions was significantly lower than that in the control group，the differences were statistically significant (P<0.05).Conclusion When Metformin is used in the patients with type 2 diabetes，it can not only reduce HOMA-IR and the incidence rate of AD，it can also improve the patient-related indicators，maintain blood sugar stability，and the incidence rate of adverse reactions is less.This method is worthy of application and promotion.
[Key words]Type 2 diabetes mellitus；Metformin；Alzheimer′s disease；Therapeutic effect
2型糖尿病是以胰島素抵抗和(或)胰岛素分泌不足为特点，是近年来极为常见的内分泌疾病，随着预期寿命提高及环境因素等改变，2型糖尿病的流行呈全球性的增高。而老化相关性疾病阿尔茨海默病(AD)与2型糖尿病的相关性目前已受到广泛关注[1-2]。AD是痴呆最主要的病因，常见于轻微的记忆或认知缺陷，其将发展至全面的认知障碍。AD多见于老年人，其流行随着年龄在65岁时的3%增长到85岁及以上人群时的50%。AD患者大脑中胰岛素信号转导的表达和活性发生改变，因而也将AD命名为“3型糖尿病”[3-6]。为了探究二甲双胍对降低2型糖尿病患者AD发病率的效果，本研究将我院收住的90例2型糖尿病患者作为研究对象，现报道如下。, 百拇医药(许晓玲)
[关键词]2型糖尿病；二甲双胍；阿尔茨海默病；治疗效果
[中图分类号] R587.1 [文献标识码] A [文章编号] 1674-4721(2018)5(a)-0135-03
[Abstract]Objective To explore the effect of Metformin on reducing the incidence rate of Alzheimer′s disease (AD) in the patients with type 2 diabetes mellitus.Methods A total of 90 patients with type 2 diabetes mellitus who were admitted to our hospital from January to December in 2017，were selected as the research subjects，and were randomly divided into observation group and control group according to the random number table，45 patients in each group.The observation group were given Metformin，and patients in the control group were given Acarbose Tablets for treatment.The effect of different treatment methods on the therapeutic effect，insulin resistance (HOMA-IR)，AD，and incidence rate of adverse reactions were compared between the two groups of patients.Results The observation group was significantly lower than that in the control group in terms of fasting plasma glucose(FBG)，2 h postprandial blood glucose(2 h PG)，fasting insulin(FINs)，glycosylated hemoglobin (HbA1c)，peripheral blood leukocyte，body mass index(BMI) (P<0.05).The blood vitamin B12 and connecting peptide (C peptide) were significantly higher than that in the control group(P<0.05).The observation group was significantly lower than that in the control group in terms of HOMA-IR(P<0.05).The incidence rate of AD and adverse reactions was significantly lower than that in the control group，the differences were statistically significant (P<0.05).Conclusion When Metformin is used in the patients with type 2 diabetes，it can not only reduce HOMA-IR and the incidence rate of AD，it can also improve the patient-related indicators，maintain blood sugar stability，and the incidence rate of adverse reactions is less.This method is worthy of application and promotion.
[Key words]Type 2 diabetes mellitus；Metformin；Alzheimer′s disease；Therapeutic effect
2型糖尿病是以胰島素抵抗和(或)胰岛素分泌不足为特点，是近年来极为常见的内分泌疾病，随着预期寿命提高及环境因素等改变，2型糖尿病的流行呈全球性的增高。而老化相关性疾病阿尔茨海默病(AD)与2型糖尿病的相关性目前已受到广泛关注[1-2]。AD是痴呆最主要的病因，常见于轻微的记忆或认知缺陷，其将发展至全面的认知障碍。AD多见于老年人，其流行随着年龄在65岁时的3%增长到85岁及以上人群时的50%。AD患者大脑中胰岛素信号转导的表达和活性发生改变，因而也将AD命名为“3型糖尿病”[3-6]。为了探究二甲双胍对降低2型糖尿病患者AD发病率的效果，本研究将我院收住的90例2型糖尿病患者作为研究对象，现报道如下。, 百拇医药(许晓玲)
参见：首页 > 医疗版 > 疾病专题 > 精神内科 > 老年性痴呆